The Protein L-Isoaspartyl (D-Aspartyl) Methyltransferase Regulates Glial-to-Mesenchymal Transition and Migration Induced by TGF-β1 in Human U-87 MG Glioma Cells.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
19 May 2022
Historique:
received: 30 04 2022
revised: 11 05 2022
accepted: 16 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 1 6 2022
Statut: epublish

Résumé

The enzyme PIMT methylates abnormal aspartyl residues in proteins. U-87 MG cells are commonly used to study the most frequent brain tumor, glioblastoma. Previously, we reported that PIMT isoform I possessed oncogenic features when overexpressed in U-87 MG and U-251 MG glioma cells. Higher levels of wild-type PIMT stimulated migration and invasion in both glioma cell lines. Conversely, PIMT silencing reduced these migratory abilities of both cell lines. These results indicate that PIMT could play a critical role in glioblastoma growth. Here, we investigated for the first time, molecular mechanisms involving PIMT in the regulation of epithelial to mesenchymal transition (EMT) upon TGF-β1 treatments. Gene array analyses indicated that EMT genes but not PIMT gene were regulated in U-87 MG cells treated with TGF-β1. Importantly, PIMT silencing by siRNA inhibited in vitro migration in U-87 MG cells induced by TGF-β1. In contrast, overexpressed wild-type PIMT and TGF-β1 had additive effects on cell migration. When PIMT was inhibited by siRNA, this prevented Slug induction by TGF-β1, while Snail stimulation by TGF-β1 was increased. Indeed, overexpression of wild-type PIMT led to the opposite effects on Slug and Snail expression dependent on TGF-β1. These data highlighted the importance of PIMT in the EMT response dependent on TGF-β1 in U-87 MG glioma cells by an antagonist regulation in the expression of transcription factors Slug and Snail, which are critical players in EMT.

Identifiants

pubmed: 35628507
pii: ijms23105698
doi: 10.3390/ijms23105698
pmc: PMC9146343
pii:
doi:

Substances chimiques

RNA, Small Interfering 0
Transforming Growth Factor beta1 0
PCMT1 protein, human EC 2.1.1.77
Protein D-Aspartate-L-Isoaspartate Methyltransferase EC 2.1.1.77

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Sciences and Engineering Research Council of Canada
ID : RGPIN-2016-04868

Références

Cancer Metastasis Rev. 2012 Jun;31(1-2):277-83
pubmed: 22215472
PLoS One. 2010 Oct 27;5(10):e13665
pubmed: 21060868
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Mol Carcinog. 2017 Mar;56(3):1088-1099
pubmed: 27649384
Oncotarget. 2017 Oct 10;8(55):94528-94538
pubmed: 29212247
Biochem Biophys Res Commun. 1992 May 29;185(1):277-83
pubmed: 1339271
Biochim Biophys Acta Mol Cell Res. 2020 Oct;1867(10):118782
pubmed: 32554164
Curr Aging Sci. 2011 Feb;4(1):8-18
pubmed: 21204776
Cell Death Dis. 2014 Oct 02;5:e1443
pubmed: 25275602
Anticancer Res. 2017 Jan;37(1):21-33
pubmed: 28011470
Brain Res Mol Brain Res. 2005 Apr 27;135(1-2):93-103
pubmed: 15857672
Biochem Cell Biol. 2006 Oct;84(5):684-94
pubmed: 17167531
IUBMB Life. 2018 Apr;70(4):291-299
pubmed: 29517839
J Cell Biol. 2015 Jun 22;209(6):895-912
pubmed: 26101221
Vet Comp Oncol. 2013 Sep;11(3):169-84
pubmed: 22404947
Oncol Rep. 2017 May;37(5):2847-2856
pubmed: 28339056
Nat Commun. 2012 Jun 26;3:927
pubmed: 22735455
J Biol Chem. 1989 Nov 25;264(33):20131-9
pubmed: 2684970
Biomed Pharmacother. 2021 Aug;140:111766
pubmed: 34082401
Oncotarget. 2018 Jan 27;9(17):13287-13300
pubmed: 29568357
Mol Cell Biochem. 2016 Feb;413(1-2):37-46
pubmed: 26738492
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Curr Pharm Des. 2015;21(10):1268-71
pubmed: 25506897
Mol Oncol. 2015 Nov;9(9):1783-98
pubmed: 26105207
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820948053
pubmed: 33089751
Neuroscience. 2015 Jun 4;295:139-50
pubmed: 25800307
Acta Pharmacol Sin. 2011 Sep;32(9):1165-72
pubmed: 21841813
Cancer Res. 2005 Jul 1;65(13):5535-43
pubmed: 15994925
Microsc Res Tech. 2001 Feb 15;52(4):401-10
pubmed: 11170299
Int J Mol Sci. 2021 Mar 30;22(7):
pubmed: 33808323
Cancers (Basel). 2014 Jan 27;6(1):226-39
pubmed: 24473088
Biochem J. 1995 Aug 1;309 ( Pt 3):993-8
pubmed: 7639720
BMC Cancer. 2010 Jun 17;10:301
pubmed: 20565806
Cell Signal. 2012 Nov;24(11):2076-84
pubmed: 22789454
Cell Res. 2009 Jan;19(1):71-88
pubmed: 19002158

Auteurs

Fatima Belkourchia (F)

Département de Chimie, Université du Québec à Montréal, C.P. 8888, Succursale Centre-Ville, Montréal, QC H3C 3P8, Canada.

Richard R Desrosiers (RR)

Département de Chimie, Université du Québec à Montréal, C.P. 8888, Succursale Centre-Ville, Montréal, QC H3C 3P8, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH